InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the detailed record of transactions filed by Ahrens Brenton Karl. Director active across 1 company, notably Iterum Therapeutics plc. Cumulatively, 5 disclosures have been recorded. Split: 0 buy · 5 sells. Total volume traded: €108k. History available since 8 September 2022. The latest transaction was disclosed on 16 September 2022 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations
Ahrens Brenton Karl is a Director of Iterum Therapeutics plc. He has reported 5 filings in total, and across the 5 most recent filings from 2022-09-12 to 2022-09-20, the reported amounts are all sales, totaling EUR 107555.